SCHEMBL7516052

SCHEMBL7516052

CC(=O)NCCc1ccsc1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 3/20 0.56
F13A1 P00488 1/20 0.56
ALDH1A1 P00352 2/20 0.51
HPGD P15428 2/20 0.51
HSD17B10 Q99714 2/20 0.51
SMN1; SMN2 Q16637 1/20 0.51
LMNA P02545 1/20 0.51
MAPT P10636 1/20 0.51
PTGS1 P23219 1/20 0.51
BLM P54132 1/20 0.51
HIF1A Q16665 1/20 0.51
OPRM1 P35372 6/20 0.50
OPRD1 P41143 4/20 0.50
OPRK1 P41145 4/20 0.50
MTNR1A P48039 1/20 0.47
TAAR1 Q96RJ0 1/20 0.46
NPC1 O15118 1/20 0.44
RAB9A P51151 1/20 0.44
TDP1 Q9NUW8 1/20 0.44
SHMT2 P34897 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3650795 0.84 OPRM1 (0.51) KDM4EALDH1A1HPGDHSD17B10SMN1; SMN2
SCHEMBL28121189 0.83 MTNR1A (0.50) KDM4EALDH1A1HPGDHSD17B10OPRM1
SCHEMBL9373709 0.82 TAAR1 (0.50) KDM4EALDH1A1HPGDHSD17B10OPRM1
SCHEMBL9430237 0.81 GRM5 (0.50) ALDH1A1HPGDLMNAMAPTNPC1
SCHEMBL28121772 0.81 POLB (0.50) KDM4EALDH1A1HPGDHSD17B10MAPT
SCHEMBL12017887 0.81 OPRM1 (0.50) KDM4EALDH1A1HPGDHSD17B10OPRM1
SCHEMBL28121194 0.80 HPGD (0.59) ALDH1A1HPGDHSD17B10MAPTOPRM1
SCHEMBL29145670 0.79 TAAR1 (0.47) KDM4EALDH1A1HPGDHSD17B10SMN1; SMN2
SCHEMBL392452 0.79 GLA (0.58) KDM4EALDH1A1HPGDHSD17B10SMN1; SMN2
SCHEMBL3300893 0.79 SPR (0.56) ALDH1A1HPGDLMNAMAPTOPRM1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-107922430-B 2-substituted benzimidazole-4-formamide compound and preparation method and application thereof 中国科学院上海药物研究所 2020-09-04 CN disclosed
WO-2018129393-A1 MU OPIOID RECEPTOR MODULATORS THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2018-07-12 WO disclosed
CN-108250128-A Compound as potassium channel modulating agents 江苏先声药业有限公司 2018-07-06 CN disclosed
CN-107922430-A 2 substituted benzimidazole, 4 Carbox amide and preparation method and application 中国科学院上海药物研究所 2018-04-17 CN disclosed
CN-106317069-A 2-substituted-benzimidazole-4-formamide compound, preparation method, and application thereof 中国科学院上海药物研究所 2017-01-11 CN disclosed
EP-1226146-A2 QUINOLINE AND NAPHTHYRIDINE CARBOXYLIC ACID ANTIBACTERIALS ABBOTT LABORATORIES (US) 2002-07-31 EP disclosed
US-20020049223-A1 Quinoline and naphthyridine carboxylic acid antibacterials ABBOTT LABORATORIES 2002-04-25 US disclosed
WO-2001032655-A2 QUINOLINE AND NAPHTHYRIDINE CARBOXYLIC ACID ANTIBACTERIALS ABBOTT LABORATORIES (US) 2001-05-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020049223-A1 Quinoline and naphthyridine carboxylic acid antibacterials NQO2, NQO1, NDUFA7 KDM4E 3740/4885F13A1 4072/4885ALDH1A1 145/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.